Cha ra c te riza tio n o f GAGE a ntig e n e xpre ssio n in thirte e n c o mmo n b re a st c a nc e r c e ll line s Pre se nte d b y: Bre nt Vo e ls Ca nkde ska Cika na Co mmunity Co lle g e F o rt T o tte n, No rth Da ko ta
Why is Bre a st Ca nc e r Re se a rc h I mpo rta nt? Ove r the c o urse o f a life time 1 in 8 wo me n will b e dia g no se d with b re a st c a nc e r. E stima te s: 200,000 wo me n a re dia g no se d pe r ye a r, a lo ng with 1,700 me n. Appro xima te ly 40,000 wo me n a nd 450 me n die a nnua lly fro m b re a st c a nc e r. I n the USA wo me n ha ve a 12% c ha nc e o f de ve lo ping inva sive b re a st c a nc e r a t so me po int in the ir live s. BRCA1 a nd BRCA2 g e ne s a re linke d to a hig h susc e ptib ility o f b re a st c a nc e r b ut o c c ur in o nly 5% o f b re a st c a nc e r pa tie nts. I n 2006 the c o st o f b re a st c a nc e r tre a tme nt in the US wa s e stima te d to b e $13.9 b illio n do lla rs. F urthe r re se a rc h ma y pro vide insig ht ino t b re a st c a nc e r pa thwa ys invo lve d in dise a se pro g re ssio n.
GAGE Antig e ns Cho se n fo r inve stig a tio n b a se d o n pre vio us mic ro a rra y re sults a nd sub se q ue nt inve stig a tio n c o nduc te d a t the Unive rsity o f No rth Da ko ta . Mic ro a rra y da ta indic a te d tha t the y we re diffe re ntia lly re g ula te d b a se d o n the pre se nc e o r a b se nc e o f the N- a nd C-te rmina l o f MT - 3. T he g o a l o f this re se a rc h is to c ha ra c te rize the e xpre ssio n o f GAGE fa mily a ntig e ns a c ro ss se ve ra l E R re c e pto r po sitive a nd ne g a tive b re a st c a nc e r c e ll line s.
Wha t a re GAGE Antig e ns? Be lo ng to a g ro up o f c a nc e r/ te stis a ntig e ns no rma lly e xpre sse d in huma n g e rmline c e lls. Also fo und to b e e xpre sse d in se ve ra l tumo r type s. GAGE a ntig e ns fa ll into thre e g ro ups. GAGE -1 ha s a uniq ue C-te rmina l se q ue nc e no o the r me mb e r ha s. GAGE s 2 thro ug h 8 a mino a c id se q ue nc e s a re 98% ide ntic a l. GAGE a ntig e ns ma y dire c t c e ll pro life ra tio n, diffe re ntia tio n, a nd the surviva l o f g e rmline c e lls. No rma lly e xpre sse d in a dult ma le g e rm c e lls, a nd a sub se t o f o o c yte s in the a dult o va ry.
GAGE Antig e ns a nd Ca nc e r Pre se nt in 26% o f b re a st c a nc e rs. Also e xpre sse d in sto ma c h c a nc e r, ne uro b la sto ma , a nd e so pha g e a l c a nc e r. E xpre ssio n is c o rre la te d to a po o r pro g no sis a nd a g g re ssive tumo r type . No rma l e xpre ssio n is limite d to immune privile g e d site s ma king the m use ful ta rg e ts fo r pro g no stic indic a to rs. Po te ntia l ta rg e ts fo r immuno the ra py.
Bre a st Ca nc e r L ine s Cha ra c te rize d ZR-75-1: E MCF R+ 7: No MT -3 e xpre ssio n, E R+ ZR-75-30: E R+ T 47D: E R+ VP267: E R- MDA-MB-157: T riple ne g a tive (No E R, VP303: E R+ b ut pro g e ste ro ne re c e pto r PR, o r HE R2 re c e pto rs) ne g a tive MDA-MB-231: T riple ne g a tive (No E R, SVCT : SV40 T ra nsfo rme d huma n b re a st PR, o r HE R2 re c e pto rs) e pithe lia l c e lls. No n-tumo rig e nic . MDA-MB-361: HS578T : T riple ne g a tive . 1-7HB2 I mmo rta lize d no n-tumo r MT -M223: Hig h a ndro g e n re c e pto r/ lo w fo rming c e ll line . e stro g e n a nd pro g e ste ro ne re c e pto r e xpre ssio n. Dihydro te sto ste ro ne inhib its pro life ra tio n.
T 47D c e ll line sho ws c o nsiste ntly hig h e xpre ssio n No te : Sta tistic s we re no t pe rfo rme d a t this po int. T he re is no sing le c o ntro l g ro up.
GAGE 12B wa s o nly e xpre sse d in the T 47D c e ll line . T he e xpre ssio n wa s a lso lo we r tha n o the r GAGE a ntig e n e xpre ssio n in T 47D c e ll line s.
GAGE 12J ha s the hig he st e xpre ssio n le ve ls in ZR-75-1 c e lls GAGE 13 ha s the hig he st e xpre ssio n le ve ls in VP303 AND MT -M223 c e lls GAGE 06 is e xpre sse d a t a ve ry lo w c o py numb e r in T 47D, MDA-MD-361 a nd ZR-75-01 c e ll line s.
Co nc lusio ns E GAGE xpre ssio n is va ria b le a mo ng st the a ntig e n e xpre ssio n is hig hly GAGE a ntig e ns in the c e ll line s va ria b le a mo ng st the c e ll line s te ste d . te ste d . T he re is no c le a r c o rre la tio n b e twe e n GAGE a ntig e n e xpre ssio n a nd e stro g e n re c e pto r sta tus. E xpre ssio n o f GAGE 2B,2C,12C, a nd 12D we re hig hly e xpre sse d in T 47D c e lls.
Re se a rc h a t Ca nkde ska Sinc e 2014 Ca nkde ska ha s a dde d Ma de po ssib le b y thre e g ra nts $250,000 wo rth o f re se a rc h (NARCH, I NBRE , I CE -T I ) e q uipme nt. All g ra nts func tio n to hire ST E M Ca nkde ska is lo o king to e xpa nd fa c ulty, a nd to c o nduc t stude nt drive n re se a rc h. its re se a rc h fa c ilitie s e ve n furthe r. L NARCH a nd I o c a l re se a rc h do ne b y lo c a l NBRE suppo rt a te n stude nts. we e k summe r re se a rc h inte rnship. I CE -T I suppo rts fa c ulty te a c hing a nd re se a rc h in ST E M.
Wo rth ke e ping in I p g E S: Cultura l e xpre ssio n Wo rksho p g
T HE S ATHYA S AI I NTERNATIONAL O RGANISATION Module 2 ORIENTATION PROGRAMME
OUT L INE 1)Junive r sity 2)Qua lific a tio ns 3)I nno va tio n in a ppo
Cha ra c te riza tio n o f Ame ric a n F o o tb a ll I njurie s in Childre
The 1.8-ft gage datum discrepancy The USGS stated in its November 5, 2008
Re po rting Mic ro a g g re ssio ns thro ug h a Mo b ile App Christy M.
City o f Sa n Anto nio , T e xa s F Y 2014 Pro po se d Budg e t Wo rk Se
RCPC, MBA Cla udio N So a re s MD, PhD, F F ina nc ia l disc lo sure s: no
The Brain Part 1/3 Phineas Gage Boston Post, September 21, 1848. Phineas
OR 62 E xpre ssway Vilas Inte rc hange T AC Me e ting Pre se nte d b y:
Lynx distribution, status, and management in southern Canada Jeff Bowman
Part 2 EDCs The Science CHE-Alaska Webinar Andrea C. Gore, PhD University
Note: for non-commercial purposes only Metabolomic profiles of childhood
Impact of radiopharmaceutical development on the management of cancer Mike
Should there be a third sex in sport? Play The Game meeting Cologne, October
Understanding Pathways to a Paradigm S hift in Toxicity Testing and
Update on Therapeutics for Muscle Regeneration Kathryn R. Wagner, M.D., Ph.D.
Key Pfizer-Sponsored Data Presentations at the American Society of Clinical
Antoxis overview Chemistry-Led pla7orm company Recently
Australian Implementation of scalp cooling for prevention of chemotherapy
Energy for Today. Opportunities for Tomorrow. July 2019 DIVERSIFIED,
Regulatory initiatives for measuring the impact of risk minimisation measures